StockData

Ecovyst vs Innospec

ECVT and IOSP side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ECVT and IOSP compare

Innospec is the larger company, worth 1.6 times as much as Ecovyst ($2.0B against $1.2B).

Ecovyst grew revenue faster over the last twelve months (44.6% versus 4.7% for Innospec).

Innospec pays a dividend yielding 2.2%; Ecovyst does not pay one.

Innospec scores higher on the StockData Score (14 against 9 for Ecovyst), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricECVTIOSP
Size and price
Market cap$1.2B$2.0B
Share price$10.97$80.39
Change, 1 year25.9%7.4%
Change, 5 years13.0%−7.9%
Beta (5Y)0.850.86
Employees6172,450
StockData Score
Total score914 (better)
Valuation score14 (better)
Growth score2 (better)1
Performance score3 (better)1
Health score36 (better)
Dividend score02 (better)
Valuation
P/E34.3×–
P/S1.2×1.1× (better)
P/B2.0×1.4× (better)
EV/EBITDA19.6×8.5× (better)
P/FCF44.8×–
FCF yield2.2%–
Fair value$7.15$109.30
Margin of safety−53.4%26.5% (better)
Growth
Revenue growth (TTM)44.6% (better)4.7%
Revenue growth, 5Y average7.8%8.3% (better)
EPS growth, 5Y average–32.1%
Profitability
Gross margin19.7%27.7% (better)
Operating margin8.5%8.8% (better)
Net margin3.7%–
FCF margin2.8%–
Return on equity5.9%–
Return on invested capital5.4%12.4% (better)
Financial health
Debt / equity0.81 (better)0.00
Net debt / EBITDA5.09–
Interest coverage3.8×–
Current ratio1.822.95 (better)
Altman Z-score1.655.12 (better)
Piotroski F-score6–
Dividends and buybacks
Dividend yield–2.2%
Years of dividend growth–12
Dividend growth, 5Y average–10.5%
Buyback yield4.9% (better)0.68%
Shareholder yield4.9% (better)2.9%
Ownership
Held by institutions100%101%
Held by insiders2.5%1.6%
Insider net buying, 12 months$137K (better)−$874K
Short interest, % of float6.2%1.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.